Alexion ups guidance

|About: Alexion Pharmaceutical... (ALXN)|By:, SA News Editor

Alexion Pharmaceuticals (ALXN) ups its 2014 EPS guidance to $4.37 to $4.47 from $3.70 - $3.80 citing improved reimbursement for Soliris in France.

Revenue guidance now $2.15B - $2.17B up from $2B - $2.02B.

Shares are up almost 3% premarket.